Disease Topics

Disease Topics

48 Disease areas packed with insight

Disease Topics

Knowledge Centres

Diagnosis, patient management, treatment strategies & decision support

Drug Database

Drug Database

Summary information on thousands of prescription drugs available in 9 languages

News

News

News written for doctors around pharmacological development

Treatment Guidelines

Clinical Guidelines

Professional association and governmental guidance on treatment

Disease Topics

Clinical Trials

Medical research & drug development - current and past landmark studies

Medical Journals

Medical Journals

Journal articles, titles and extracts from respected publishers

Disease Topics

Medical Apps

All the latest free and paid-for Apps selected for doctors

Welcome to epgonline.org - the website for healthcare professionals

What's new? The Type 2 Diabetes Knowledge Centre

Based on current estimates, the global prevalence of type 2 diabetes has increased almost 10 fold since 1985 and is expected to rise to 552 million by 2030,1 and when absolute numbers of people with diabetes are considered, it is South East Asia and the West Pacific that are expected to experience the highest increases in prevalence over the coming years.2

Type 2 diabetes can be defined according to fasting plasma glucose (FPG) and 2 hour plasma glucose levels. The first is assessed after 8-10 hours of fasting, usually in the morning. The second is measured by an oral glucose tolerance test (OGTT) assessing venous plasma glucose 2 hour after ingestion of a 75g oral glucose load.

Type 2 Diabetes involves two primary pathogenic mechanisms; insulin resistance and impaired insulin secretion. Insulin resistance occurs when the insulin in the body does not exert sufficient action proportional to its blood concentration.3,4 Impaired insulin secretion is characterised by decreased glucose responsiveness, and is observed before the clinical onset of disease.4

Latest News

FDA approves Eliquis for DVT and PE (VTE).- BMS + Pfizer

23-Aug-2014

BMS and Pfizer Inc. announced the ...

Cubist Pharma files ceftolozane/tazobactam at EMA for Urinary Tract and Intra Abdominal Infections.

23-Aug-2014

Cubist Pharmaceuticals, Inc. ...

BAX 855 success in Phase III trial for Haemophilia A prophylaxis- Baxter

22-Aug-2014

Baxter International Inc. announced ...

FDA approves Arnuity Ellipta for treatment of Asthma- GSK

22-Aug-2014

GlaxoSmithKline plc announced that ...

Eisai files Fycompa at EMA and FDA for uncontrolled primary generalized Tonic-Clonic Seizures.

22-Aug-2014

Eisai has filed its anti-epileptic ...

Ixekizumab superior to etanercept in Phase III trials for plaque Psoriasis- Eli Lilly

22-Aug-2014

Eli Lilly and Company's ...

NICE recommends Revlimid for specific Myelodysplastic syndromes- Celgene

21-Aug-2014

In new final draft guidance, the ...

Recent Updates

Drugs

Clinical Guidelines

Guidelines for prevention and control of group A streptococcal infection in acute healthcare and maternity settings in the UK

Guidelines for evaluation and management of urticaria in adults and children

Antibiotics for early-onset neonatal infection: Antibiotics for the prevention and treatment of early-onset neonatal infection

Guidelines for antiretroviral treatment of HIV-2-positive individuals

Medical Journals

The value of CMV IgG avidity and immunoblot for timing the onset of primary CMV infection in pregnancy

Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial

Outcomes after listing with a requirement for a prospective crossmatch in pediatric heart transplantation

Dual effect of advanced glycation end products in pancreatic islet apoptosis

epgonline.org Social